Controlled release and taste masking oral pharmaceutical composition
AssigneeCosmo Technologies Limited
InventorsRoberto Villa, Massimo Pedrani, Mauro Ajani, Lorenzo Fossati
Life of this patent
Estimating the term…
Abstract
Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.
Claims12
An oral pharmaceutical composition administered to a human, wherein said oral pharmaceutical composition is in the form of a tablet, said tablet comprising:
- (a) a tablet core comprising:
- (i) 9 mg of budesonide;
- and
- (ii) a macroscopically homogenous composition comprising stearic acid and/or salt thereof, lecithin, and hydroxypropyl cellulose, wherein said budesonide is dispersed in said macroscopically homogeneous composition;
- and
- (b) a coating on said tablet core consisting essentially of a gastro-resistant film, wherein said gastro-resistant film consists essentially of a mixture of 8 mg of a first methacrylic acid copolymer and 8 mg of a second methacrylic acid copolymer, and
- wherein said oral pharmaceutical composition provides a Tlag of said budesonide in said human of about 6.79±3.24 hours following said administration of said oral pharmaceutical composition to said human.
An oral pharmaceutical composition administered to a human, wherein said oral pharmaceutical composition is in the form of a tablet, said tablet comprising:
- (a) a tablet core comprising:
- (i) 9 mg of budesonide;
- and
- (ii) a macroscopically homogenous composition comprising stearic acid and/or salt thereof, lecithin, and hydroxypropyl cellulose, wherein said budesonide is dispersed in said macroscopically homogeneous composition;
- and
- (b) a coating on said tablet core consisting essentially of a gastro-resistant film, wherein said gastro-resistant film consists essentially of a mixture of 8 mg of a first methacrylic acid copolymer and 8 mg of a second methacrylic acid copolymer, and
- wherein said oral pharmaceutical composition provides a (Tmax-Tlag) of said budesonide in said human of about 7.21±5.49 hours following said administration of said oral pharmaceutical composition to said human.
An oral pharmaceutical composition administered to a human, wherein said oral pharmaceutical composition is in the form of a tablet, said tablet consisting essentially of:
- (a) a tablet core comprising:
- (i) 9 mg of budesonide;
- and
- (ii) a macroscopically homogenous composition comprising stearic acid and/or salt thereof, lecithin, and hydroxypropyl cellulose, wherein said budesonide is dispersed in said macroscopically homogeneous composition;
- and
- (b) a coating on said tablet core consisting essentially of a gastro-resistant film, wherein said gastro-resistant film consists essentially of a mixture of 8 mg of a first methacrylic acid copolymer and 8 mg of a second methacrylic acid copolymer, and
- wherein said oral pharmaceutical composition provides a Tlag of said budesonide in said human of about 6.79±3.24 hours following said administration of said oral pharmaceutical composition to said human.
An oral pharmaceutical composition administered to a human, wherein said oral pharmaceutical composition is in the form of a tablet, said tablet consisting essentially of:
- (a) a tablet core comprising:
- (i) 9 mg of budesonide;
- and
- (ii) a macroscopically homogenous composition comprising stearic acid and/or salt thereof, lecithin, and hydroxypropyl cellulose, wherein said budesonide is dispersed in said macroscopically homogeneous composition;
- and
- (b) a coating on said tablet core consisting essentially of a gastro-resistant film, wherein said gastro-resistant film consists essentially of a mixture of 8 mg of a first methacrylic acid copolymer and 8 mg of a second methacrylic acid copolymer, and
- wherein said oral pharmaceutical composition provides a (Tmax-Tlag) of said budesonide in said human of about 7.21±5.49 hours following said administration of said oral pharmaceutical composition to said human.
An oral pharmaceutical composition administered to a human, wherein said oral pharmaceutical composition is in the form of a tablet, said tablet comprising:
- (a) a tablet core comprising:
- (i) 9 mg of budesonide;
- and
- (ii) a macroscopically homogenous composition comprising stearic acid and/or salt thereof, lecithin, and hydroxypropyl cellulose, wherein said budesonide is dispersed in said macroscopically homogeneous composition;
- and
- (b) a coating on said tablet core consisting essentially of a gastro-resistant film, wherein said gastro-resistant film consists essentially of a mixture of 8 mg of a first methacrylic acid copolymer and 8 mg of a second methacrylic acid copolymer, and
- wherein said oral pharmaceutical composition provides a Tlag of said budesonide in said human of from about 1 hour to about 12 hours following said administration of said oral pharmaceutical composition to said human.
An oral pharmaceutical composition administered to a human, wherein said oral pharmaceutical composition is in the form of a tablet, said tablet consisting essentially of:
- (a) a tablet core comprising:
- (i) 9 mg of budesonide;
- and
- (ii) a macroscopically homogenous composition comprising stearic acid and/or salt thereof, lecithin, and hydroxypropyl cellulose, wherein said budesonide is dispersed in said macroscopically homogeneous composition;
- and
- (b) a coating on said tablet core consisting essentially of a gastro-resistant film, wherein said gastro-resistant film consists essentially of a mixture of 8 mg of a first methacrylic acid copolymer and 8 mg of a second methacrylic acid copolymer, and
- wherein said oral pharmaceutical composition provides a Tlag of said budesonide in said human of from about 1 hour to about 12 hours following said administration of said oral pharmaceutical composition to said human.
Dependencies are inferred from the claim text.